 SAN FRANCISCO, Sept. 25, 2021 PRNewswire -- Invitae NYSE: NVTA, a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. 